Whitehawk Therapeutics, Inc. (WHWK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.38 Million) by net assets ($157.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Whitehawk Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Whitehawk Therapeutics, Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Whitehawk Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyungin Synthe
KO:012610
|
0.064x |
|
Journey Medical Corp
NASDAQ:DERM
|
-0.092x |
|
Seoho Electric Co.Ltd
KQ:065710
|
-0.073x |
|
Iljin Diamond
KO:081000
|
-0.018x |
|
Protech Mitra Perkasa Tbk PT
JK:OASA
|
-0.061x |
|
Mondi Turkey Oluklui Mukavva Kagit ve Ambalaj Sanayi A.S.
IS:MNDTR
|
N/A |
|
MNtech Co. Ltd
KQ:095500
|
0.089x |
|
Zapata Computing Holdings Inc. Common Stock
NASDAQ:ZPTA
|
0.032x |
Annual Cash Flow Conversion Efficiency for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Whitehawk Therapeutics, Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see WHWK stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-59.55 Million | -1.135x | -100.08% |
| 2023-12-31 | $105.19 Million | $-59.66 Million | -0.567x | -80.96% |
| 2022-12-31 | $158.38 Million | $-49.64 Million | -0.313x | -90.67% |
| 2021-12-31 | $136.41 Million | $-22.42 Million | -0.164x | -116.09% |
| 2020-12-31 | $-12.43 Million | $-12.70 Million | 1.022x | +22.50% |
| 2019-12-31 | $-9.09 Million | $-7.58 Million | 0.834x | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more